Chemocentryx, Inc.

Andrew Mk Pennell

Sreenivas Punna

Solomon Ungashe

Trevor T Charvat

Yibin Zeng

Cheng Hu

Anita Melikian

Edward J Sullivan

Jeff Jin

William D Thomas

Aaron Novack

Penglie Zhang

Jay Patrick Powers

James Bradley Aggen

Yandong Li

Daniel J Dairaghi

Lianfa Li

Brian E McMaster

Xuefei Tan

Jj Kim Wright

Subrabrata Sen

Arindrajit Basak

Zheng Wei

Jimmie Moore

Daniel Dairaghi

Derek Hansen

John Jessen Wright

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

3-(imidazolyl)-pyrazolo[3,4-b]pyridines

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Substituted piperazines

Growing community of inventors

San Francisco, CA, United States of America

Andrew Mk Pennell